The downgrade reflects skepticism regarding the upcoming Phase 3 trial results for Opakalim. Analysts warned that even in an optimistic scenario, the data likely will appear undifferentiated compared to azetukalnar, an investigative treatment currently in development by Xenon Pharmaceuticals. This lack of clear clinical advantage threatens the consensus projection that Opakalim could generate $1 billion in peak annual sales.

Beyond the competitive landscape, the firm cited broader financial risks, noting that Biohaven faces a tightening cash runway. With the company's only other major 2026 catalyst—a drug candidate in the obesity space—carrying limited derisking value, analysts opted to cut their price target from $12 to $11. Despite Monday’s retreat, the stock retains a 31% gain for the year.